New generation of coronavirus vaccine shows promising results

Researchers at Karolinska Institutet in Sweden are developing a coronavirus vaccine designed to be less sensitive to mutations and equipped for future strains. The vaccine showed promising results in mice in a newly published study in EMBO Molecular Medicine, and the researchers now hope to be able to take it to safety studies on humans.

“This is a new generation of corona vaccine,” says Matti Sällberg, professor at the Department of Laboratory Medicine, Karolinska Institutet, and the study’s joint last author with Ali Mirazimi, adjunct professor at the same department. “The idea is that it will give broader protection that more resembles that gained after an actual infection and will be a bit more future-proof than the vaccines currently in use.”

Different types of vaccine have been highly instrumental in impeding the pandemic caused by the coronavirus SARS-CoV-2. One challenge is the virus’s mutability, which is to say its ability to change to avoid the human defence response.

Most current vaccines are based on using parts of the coronavirus’s so-called spike protein to trigger the body’s immune response to the virus. It is a good vaccine protein to use, but unfortunately it is the spike protein where frequent mutations occur, which can impact the vaccines’ effectiveness.

Contains more parts of the virus

The researchers at Karolinska Institutet are therefore developing a vaccine containing more parts of the virus, including ones that do not mutate at the same rate as the spike protein.

Source: Read Full Article